Form 8-K - Current report:
SEC Accession No. 0001739410-25-000029
Filing Date
2025-03-13
Accepted
2025-03-13 08:11:19
Documents
15
Period of Report
2025-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlyb-20250313.htm   iXBRL 8-K 28455
2 EX-99.1 rlyb-20250313xex991pressre.htm EX-99.1 75612
6 img96626370_0.jpg GRAPHIC 7155
  Complete submission text file 0001739410-25-000029.txt   255039

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rlyb-20250313.xsd EX-101.SCH 1773
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rlyb-20250313_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rlyb-20250313_pre.xml EX-101.PRE 13575
17 EXTRACTED XBRL INSTANCE DOCUMENT rlyb-20250313_htm.xml XML 2917
Mailing Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510
Business Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510 203- 859-3820
Rallybio Corp (Filer) CIK: 0001739410 (see all company filings)

EIN.: 851083789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40693 | Film No.: 25733899
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)